Form 4: TENAX Director Boosts Stake with Common Stock Purchases

Sentiment:

Insider Transaction Report 19 November 2025 6:43 PM

📋All filings for Tenax Therapeutics, INC

A director at Tenax Therapeutics, June Sherie Almenoff, increased her direct beneficial ownership of common stock through open market purchases.

Summary

Director June Sherie Almenoff acquired 93 shares of Tenax Therapeutics, Inc. common stock on November 17, 2025, at a price of $7.15 per share.
An additional 1,900 shares of common stock were purchased on November 18, 2025, at a weighted average price of $7.5157 per share, with individual trades ranging from $7.45 to $7.70.
Following these transactions, Ms. Almenoff directly beneficially owns 1,993 shares of common stock.
Ms. Almenoff also holds several stock options, including 100,000 shares exercisable at $5.94 expiring December 10, 2034, and 80,000 shares exercisable at $5.75 expiring July 1, 2035.
The reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: Director June Sherie Almenoff's open market purchases of common stock suggest confidence in the company's future prospects, which is generally viewed positively by investors.

Positives

Director June Sherie Almenoff increased her direct beneficial ownership of common stock, signaling confidence in the company's future prospects.
The transactions were executed pursuant to a Rule 10b5-1 plan, indicating a pre-planned and transparent approach to insider trading.

Future Outlook

Industry Context

Insider purchases by a director can be interpreted by the market as a signal of management's confidence in the company's current valuation and future prospects, potentially indicating a belief that the stock is undervalued or that positive developments are anticipated. This is a common signal observed across various industries, including biotechnology, where future drug development and regulatory milestones can significantly impact stock performance.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Insider Trading Policy	The reported transactions were made pursuant to a Rule 10b5-1(c) plan, which provides an affirmative defense against insider trading allegations by demonstrating that trades were pre-planned.	NA	Enhances transparency and reduces the risk of insider trading accusations for the reporting person, aligning with best practices for corporate governance regarding insider transactions.

Stakeholder Impact

Shareholders: May view the director's purchases as a positive signal of confidence in the company's value and future performance, potentially influencing investor sentiment.

Key Dates

Date	Description
06/10/2022	Date stock option to buy 4 shares at $3,200 became exercisable.
06/09/2023	Date stock option to buy 4 shares at $992 became exercisable.
11/17/2025	Date of common stock acquisition (93 shares at $7.15).
11/18/2025	Date of common stock acquisition (1,900 shares at $7.5157 weighted average).
11/19/2025	Signature date of the reporting person's attorney-in-fact.
12/10/2025	Date stock option to buy 100,000 shares at $5.94 becomes exercisable.
07/01/2026	Date stock option to buy 80,000 shares at $5.75 becomes exercisable.
06/10/2031	Expiration date of stock option to buy 4 shares at $3,200.
06/09/2032	Expiration date of stock option to buy 4 shares at $992.
12/10/2034	Expiration date of stock option to buy 100,000 shares at $5.94.
07/01/2035	Expiration date of stock option to buy 80,000 shares at $5.75.

Recommendation

hold

While director purchases signal confidence, a comprehensive investment decision requires evaluating the company's full financial performance, strategic outlook, and market conditions beyond this single insider transaction. This filing alone does not provide sufficient information to warrant a 'buy' or 'sell' recommendation.

Keywords

TENAX THERAPEUTICS, TENX, Insider Trading, Form 4, Stock Purchase, Director, Beneficial Ownership, Equity, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.